(Circulation. 1996;93:1579-1587.)
© 1996 American Heart Association, Inc.
Articles |
Heart Valve Involvement (Libman-Sacks Endocarditis) in the Antiphospholipid Syndrome
From the Department of Medicine "B" and Research Unit of Autoimmune Diseases, Sheba Medical Center (affiliated with Sackler Faculty of Medicine, Tel-Aviv University), Tel-Hashomer, Israel.
Correspondence to Yehuda Shoenfeld, MD, Department of Medicine "B," Sheba Medical Center, Tel-Hashomer 52621, Israel.
Abstract The antiphospholipid syndrome (APS) is defined by the presence of anti-phospholipid antibodies (aPLs) and venous or arterial thrombosis, recurrent pregnancy loss, or thrombocytopenia. The syndrome can be either primary or secondary to an underlying condition, most commonly systemic lupus erythematosus (SLE). Echocardiographic studies have disclosed heart valve abnormalities in about a third of patients with primary APS. SLE patients with aPLs have a higher prevalence of valvular involvement than those without these antibodies. Valvular lesions associated with aPLs occur as valve masses (nonbacterial vegetations) or thickening. These two morphological alterations can be combined and are thought to reflect the same pathological process. Both can be associated with valve dysfunction, although such association is much more common with the latter alteration. The predominant functional abnormality is regurgitation; stenosis is rare. The mitral valve is mainly affected, followed by the aortic valve. Valvular involvement usually does not cause clinical valvular heart disease. The presence of aPLs seems to further increase the risk for thromboembolic complications, mainly cerebrovascular, posed by valve lesions. Superadded bacterial endocarditis is rare but may be difficult to distinguish from pseudoinfective endocarditis. The current therapeutic guidelines are those for APS in general. Secondary antithrombotic prevention with long-term, high-intensity oral anticoagulation is advised. The efficacy of aspirin, either alone or in combination, is yet to be assessed. Corticosteroids are not beneficial and may even facilitate valve damage. Immunosuppressive agents should only be used for the treatment of an underlying condition. Current data suggest a role for aPLs in the pathogenesis of valvular lesions. aPLs may promote the formation of valve thrombi. These antibodies may also act by another mechanism, as indicated by the finding of subendothelial deposits of immunoglobulins, including anti-cardiolipin antibodies, and of colocalized complement components in deformed valves from patients with APS.
Key Words: antibodies • pathology • rheumatic heart disease • valves
This article has been cited by other articles:
 |
|
 |
|
  S. C. Plastiras, C. A. Pamboucas, M. Tektonidou, and S. T. Toumanidis Real-time three-dimensional echocardiography in evaluating Libman-Sacks vegetations Eur J Echocardiogr, November 28, 2009; (2009) jep172v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rajamani, S. Chaturvedi, Z. Jin, S. Homma, R. L. Brey, B. C. Tilley, R. L. Sacco, J.L.P. Thompson, J.P. Mohr, S. R. Levine, et al. Patent Foramen Ovale, Cardiac Valve Thickening, and Antiphospholipid Antibodies as Risk Factors for Subsequent Vascular Events: The PICSS-APASS Study Stroke, July 1, 2009; 40(7): 2337 - 2342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gorki, V. Malinovski, and R. D.L. Stanbridge The antiphospholipid syndrome and heart valve surgery Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 168 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Lonnebakken and E. Gerdts Libman-Sacks endocarditis and cerebral embolization in antiphospholipid syndrome Eur J Echocardiogr, January 1, 2008; 9(1): 192 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Asopa, A. Patel, O. A. Khan, R. Sharma, and S. K. Ohri Non-bacterial thrombotic endocarditis Eur. J. Cardiothorac. Surg., November 1, 2007; 32(5): 696 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tincani, C. B. Rebaioli, M. Taglietti, and Y. Shoenfeld Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus Rheumatology, October 1, 2006; 45(suppl_4): iv8 - iv13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Rottem, I Krause, A Fraser, L Stojanovich, J Rovensky, and Y Shoenfeld Autoimmune Hemolytic Anaemia in the Antiphospholipid Syndrome Lupus, July 1, 2006; 15(7): 473 - 477. [Abstract] [PDF]
|
|
|
|
|
|
M. Blank, I. Krause, L. Magrini, G. Spina, J. Kalil, S. Jacobsen, H. J. Thiesen, M. W. Cunningham, L. Guilherme, and Y. Shoenfeld Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome Rheumatology, July 1, 2006; 45(7): 833 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Krause, S Lev, A Fraser, M Blank, M Lorber, L Stojanovich, J Rovensky, J Chapman, and Y Shoenfeld Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome Ann Rheum Dis, October 1, 2005; 64(10): 1490 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Tincani, C Biasini-Rebaioli, R Cattaneo, and P Riboldi Nonorgan specific autoantibodies and heart damage Lupus, September 1, 2005; 14(9): 656 - 659. [Abstract] [PDF]
|
|
|
|
|
|
F Tenedios, D Erkan, and M D Lockshin Cardiac involvement in the antiphospholipid syndrome Lupus, September 1, 2005; 14(9): 691 - 696. [Abstract] [PDF]
|
|
|
|
|
|
M Blank, A Aron-Maor, and Y Shoenfeld From rheumatic fever to Libman-Sacks endocarditis: is there any possible pathogenetic link? Lupus, September 1, 2005; 14(9): 697 - 701. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M. Baddour, W. R. Wilson, A. S. Bayer, V. G. Fowler Jr, A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, et al. Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America Circulation, June 14, 2005; 111(23): e394 - e434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Erdogan, M. T. Goren, R. Diz-Kucukkaya, and M. Inanc Assessment of Cardiac Structure and Left Atrial Appendage Functions in Primary Antiphospholipid Syndrome: A Transesophageal Echocardiographic Study Stroke, March 1, 2005; 36(3): 592 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 APASS Investigators Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke JAMA, February 4, 2004; 291(5): 576 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Berkun, A. Elami, K. Meir, D. Mevorach, and Y. Naparstek Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 414 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Morelli, M L Bernardo, F Viganego, A Sgreccia, P De Marzio, F Conti, R Priori, and G Valesini Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus Lupus, November 1, 2003; 12(11): 805 - 812. [Abstract] [PDF]
|
|
|
|
|
|
M Lockshin, F Tenedios, M Petri, G McCarty, R Forastiero, S Krilis, A Tincani, D Erkan, M A Khamashta, and Y Shoenfeld Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report Lupus, July 1, 2003; 12(7): 518 - 523. [Abstract] [PDF]
|
|
|
|
 |
|
 H. G. Bulckaen, F. L. Puisieux, E. D. Bulckaen, C. Di Pompeo, O. M. Bouillanne, A. A. Watel, A.-L. M. Fauchais, P. De Groote, and A. Millaire Antiphospholipid Antibodies and the Risk of Thromboembolic Events in Valvular Heart Disease Mayo Clin. Proc., March 1, 2003; 78(3): 294 - 298. [Abstract] [PDF]
|
|
|
|
|
|
K Jensen-Urstad, E Svenungsson, U de Faire, A Silveira, J L Witztum, A Hamsten, and J Frostegard Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease Lupus, November 1, 2002; 11(11): 744 - 752. [Abstract] [PDF]
|
|
|
|
|
|
H Ilarraza, M F Marquez, A Alcocer, J L Banales, A H Nava, and P A Reyes Anticardiolipin antibodies are not associated with rheumatic heart disease Lupus, December 1, 2001; 10(12): 873 - 875. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Lagana, L. Baratta, L. Tubani, V. Golluscio, M. Delfino, and F. R. Fanelli Myocardial Infarction with Normal Coronary Arteries in a Patient with Primary Antiphospholipid Syndrome: Case Report and Literature Review Angiology, November 1, 2001; 52(11): 785 - 788. [Abstract] [PDF]
|
|
|
|
 |
|
 M Suguta, Y Hoshino, and S Naito Novel expression of VCAM-1 on the mitral valve in a patient with primary antiphospholipid antibody syndrome Heart, November 1, 2000; 84(5): 10e - 10. [Full Text]
|
|
|
|
 |
|
 Y S Haviv Association of anticardiolipin antibodies with vascular injury: possible mechanisms Postgrad. Med. J., October 1, 2000; 76(900): 625 - 628. [Full Text]
|
|
|
|
|
|
M Turiel, S Muzzupappa, B Gottardi, C Crema, P Sarzi-Puttini, and E Rossi Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography Lupus, July 1, 2000; 9(6): 406 - 412. [Abstract] [PDF]
|
|
|
|
|
|
M Bijl, J Brouwer, and G G. Kallenberg Grand Rounds from International Lupus Centres Cardiac abnormalities in SLE: pancarditis Lupus, May 1, 2000; 9(4): 236 - 240. [Abstract] [PDF]
|
|
|
|
 |
|
 B.M Weiss and O.M Hess Pulmonary vascular disease and pregnancy: current controversies, management strategies, and perspectives Eur. Heart J., January 2, 2000; 21(2): 104 - 115. [PDF]
|
|
|
|
|
|
R. M Nagler, M. Lorber, Y. Ben-Arieh, D. Laufer, and S. Pollack Generalized periodontal involvement in a young patient with systemic lupus erythematosus Lupus, November 1, 1999; 8(9): 770 - 772. [Abstract] [PDF]
|
|
|
|
|
|
A Afek, Y Shoenfeld, R Manor, I Goldberg, L Ziporen, J George, S Polak-Charcon, M C Amigo, R Garcia-Torres, R Segal, et al. Increased endothelial cell expression of a3{beta}1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome Lupus, September 1, 1999; 8(7): 502 - 507. [Abstract] [PDF]
|
|
|
|
 |
|
 H. G. Rennke and M. Laposata Case 18-1999- A 54-Year-Old Woman with Acute Renal Failure and Thrombocytopenia N. Engl. J. Med., June 17, 1999; 340(24): 1900 - 1908. [Full Text] [PDF]
|
|
|
|
|
|
E Diri, E Cucurull, A E Gharavi, D Kapoor, E A Mendez, E Scopelitis, and W A Wilson Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and a{beta}2 glycoprotein-I is the most frequent isotype Lupus, May 1, 1999; 8(4): 263 - 268. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Tanne, L. D'Olhaberriague, L. R. Schultz, L. Salowich-Palm, K. L. Sawaya, and S. R. Levine Anticardiolipin antibodies and their associations with cerebrovascular risk factors Neurology, April 1, 1999; 52(7): 1368 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Wu, E Svenungsson, I Gunnarsson, B Andersson, I Lundberg, L S. Elinder, and J Frostegard Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE Lupus, February 1, 1999; 8(2): 142 - 150. [Abstract] [PDF]
|
|
|
|
|
|
Y Shoenfeld, A Gharavi, and T Koike b2GP-I in the anti phospholipid (Hughes') syndrome--from a cofactor to an autoantigen -- from induction to prevention of antiphospholipid syndrome Lupus, October 1, 1998; 7(8): 503 - 506. [PDF]
|
|
|
|
|
|
J. George, A. Afek, B. Gilburd, M. Blank, Y. Levy, A. Aron-Maor, H. Levkovitz, A. Shaish, I. Goldberg, J. Kopolovic, et al. Induction of Early Atherosclerosis in LDL-Receptor–Deficient Mice Immunized With ß2-Glycoprotein I Circulation, September 15, 1998; 98(11): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J-C. Piette Review : Towards improved criteria for the antiphospholipid syndrome Lupus, January 1, 1998; 7(2_suppl): S149 - S157. [Abstract] [PDF]
|
|
|
|
|
|
Y. Shoenfeld and L. Ziporen Review : Lessons from experimental APS models Lupus, January 1, 1998; 7(2_suppl): S158 - S161. [Abstract] [PDF]
|
|
|
|
|
|
J.-C. Piette, Z. Amoura, T. Papo, G. M. McCarthy, D. J. McCarty, C. A. Roldan, and M. H. Crawford Valvular Heart Disease and Systemic Lupus Erythematosus N. Engl. J. Med., May 1, 1997; 336(18): 1324 - 1325. [Full Text]
|
|
|
|
|
|
C. A. Roldan, B. K. Shively, and M. H. Crawford An Echocardiographic Study of Valvular Heart Disease Associated with Systemic Lupus Erythematosus N. Engl. J. Med., November 7, 1996; 335(19): 1424 - 1430. [Abstract] [Full Text] [PDF]
|
|